Company Overview and News

 
IOC to invest Rs 1.4 lakh crore to double refining capacity

2018-03-31 moneycontrol
India's biggest oil firm IOC today said it plans to invest about Rs 1.43 lakh crore to nearly double its oil refining capacity to 150 million tonnes and boost petrochemical production by 2030.
Upvote Downvote

 
Indian Oil to invest Rs1.4 trillion to double refining capacity

2018-03-31 livemint
New Delhi: India’s biggest oil firm IOC on Saturday said it plans to invest about Rs1.43 trillion to nearly double its oil refining capacity to 150 million tonnes and boost petrochemical production by 2030.
Upvote Downvote

 
Market Update: PSU Bank index up 1% led by SBI; CNX IT drags as Wipro falls 2%; GAIL, HPCL shed up to 4%

2018-03-26 moneycontrol
The Indian equity market was trading almost flat on Monday morning with the Nifty trading lower by 9 points, trading below the 10,000 mark at 9988 while the Sensex was up 25 points or 0.08 percent.
Upvote Downvote

 
CPCL goes for ₹3,110-cr upgrade

2018-02-27 thehindubusinessline
Union Minister Dharmendra Pradhan at the inauguration of CPCL’s residue upgradation project in Chennai on Tuesday; (right) a view of the project at CPCL’s Manali refinery - R Ragu
Upvote Downvote

 
CPCL’s ₹3,110-cr residue upgradation project goes on stream

2018-02-27 thehindubusinessline
Petroleum Minister Dharmendra Pradhan today formally launched the Rs 3,110 crore residue upgradation project of Indian Oil Group company, Chennai Petroleum Corporation Ltd, here. The city-based company embarked on a value addition at the Manali Refinery, for upgradation of residue to high value liquids such as diesel, naphtha and LPG through delayed coking process at an investment of Rs 3,110 crore.
Upvote Downvote

 
CPCL#39;s Rs 3,110 cr Residue Upgradation Project goes on stream

2018-02-27 moneycontrol
Union Petroleum Minister Dharmendra Pradhan today formally launched the Rs 3,110 crore residue upgradation project of Indian Oil Group company, Chennai Petroleum Corporation Ltd, here.
Upvote Downvote

 
Indian Oil Corp to invest Rs 7 billion to expand refining capacity by 2030

2018-02-18 business-standard
Indian Oil Corp (IOC) will invest Rs 7 billion to raise its oil refining capacity by about a quarter by 2030 as it takes the lead to meet rising energy needs of the country. IOC will expand its refining capacity to 116.55 million tonnes per annum (MTPA) by 2030 from the current 80.7 MTPA with an investment of about Rs 7 billion, a top company official said. India's current refining capacity of 247.
Upvote Downvote

 
Indian Oil to invest Rs70,000 crore to expand refining capacity

2018-02-18 livemint
New Delhi: Indian Oil Corp (IOC) will invest Rs70,000 crore to raise its oil refining capacity by about a quarter by 2030 as it takes the lead to meet rising energy needs of the country. IOC will expand its refining capacity to 116.55 million tonnes per annum (MTPA) by 2030 from the current 80.7 MTPA with an investment of about Rs70,000 crore, a top company official said.
Upvote Downvote

 
Two insurance cos, IDFC Bank results

2018-01-18 thehindubusinessline
Friday will see a host of companies that are widely followed by analysts reporting their quarterly numbers for the period ended December 2017.
Upvote Downvote

 
Market Update: HDFC, TCS hit new 52-week high; Yes Bank, Tata Motors most active

2017-11-07 moneycontrol
The Indian benchmark indices on Tuesday morning were trading flat with the Nifty down 0.05 percent or 7.2 points while the Sensex was up 18.87 points at 33750.
Upvote Downvote

 
IOC drops Chennai Petroleum merger plan

2017-10-12 business-standard
As a premium subscriber you get an across device unfettered access to a range of services which include:
Upvote Downvote

 
Chennai Petroleum Corporation to set up refinery at Nagapattinam

2017-09-26 indiainfoline
The board of directors of Chennai Petroleum Corporation recommended the proposal for setting up a new refinery.
Upvote Downvote

 
Board of Chennai Petroleum approves setting up of a new 9 MMTPA refinery

2017-09-25 indiainfoline
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.
Upvote Downvote

 
IOC board clears CPCL's Rs 27k-cr Cauvery Basin refinery project

2017-09-25 business-standard
The board of directors of Indian Oil Corporation Ltd (IOCL) gave an in-principle approval for the proposal of its subsidiary Chennai Petroleum Corporation Ltd (CPCL) to set up a refinery in Tamil Nadu at an estimated cost of Rs 27,460 crore.
Upvote Downvote

 
Strides Shasun receives USFDA approval for Omega-3-Acid Ethyl Esters capsules

2017-09-20 indiainfoline
Strides Shasun announced that it has received approval from the USFDA for Omega-3-Acid Ethyl Esters capsules, a generic version of Lovaza.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...